Fosun Pharma of Shanghai closed its $182 million in-licensing of China rights to balixafortide with Switzerland 's Polyphor AG . Balixafortide is a selective blocker of CXCR4 with multiple mechanisms, which is in an international Phase III trial for recurrent breast cancer. Fosun has made the initial payment of $15 million, and it agreed to pay future development milestones of $19 million and sales milestones of $148 million, plus royalties. More details.... Stock Symbols: (SH: 600196; HK: 02196) Share this with colleagues: // //